Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.
Journal of the National Cancer Institute. Monographs|December 15, 2022
Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical TrialsJennifer Le-Rademacher, Supriya Mohile, Joseph Unger, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 23, 2020
Current Practices for Screening and Addressing Financial Hardship within the NCI Community Oncology Research ProgramLaurie E McLouth, Chandylen L Nightingale, Emily V Dressler, et al.
Cancer Chemotherapy and Pharmacology|May 3, 2013
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumorsAntoinette R Tan, Darlene G Gibbon, Mark N Stein, et al.
Psychiatric Services (Washington, D.C.)|November 15, 2022
Guidelines to Establish an Equitable Mobile Health EcosystemKaren L Fortuna, Arya Kadakia, Theodore D Cosco, et al.
JNCI Cancer Spectrum|April 27, 2023
Feasibility and acceptability of an online intervention to enhance hopefulness among oncology professionalsBenjamin W Corn, David B Feldman, Ishwaria M Subbiah, et al.
Cancers|October 13, 2021
Increased Circulating Levels of Galectin Proteins in Patients with Breast, Colon, and Lung CancerBailey B Blair, Avery T Funkhouser, Jane L Goodwin, et al.
Cancers|June 10, 2022
KIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung CancerAvery T Funkhouser, Alexander M Strigenz, Bailey B Blair, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2014
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancerJoe J Stephenson, John Nemunaitis, Anil A Joy, et al.
Cancer|November 2, 2020
Caregiver engagement practices in National Cancer Institute Clinical Oncology Research Program settings: Implications for research to advance the fieldChandylen L Nightingale, Katherine R Sterba, Laurie E McLouth, et al.
Pageof 6